PET and MFC MRD results at PM
| . | Overall population . | Daratumumab-treated patients . |
|---|---|---|
| PM PET | ||
| No. of patients | 175 | 133 |
| Complete response | 113 (64.6) | 82 (61.7) |
| Unconfirmed complete response | 48 (27.4) | 40 (30.0) |
| PR | 14 (8.0) | 11 (8.3) |
| PET-negative | 161 (92.0) | 122 (91.7) |
| PET-positive | 14 (8.0) | 11 (8.3) |
| PM MFC | ||
| No. of patients | 174 | 132 |
| MFC-negative | 140 (80.5) | 109 (82.6) |
| PET-positive | 8 (4.6) | 6 (4.5) |
| PET-negative | 132 (76.0) | 103 (78.0) |
| MFC-positive | 34 (19.5) | 23 (17.4) |
| PET-positive | 6 (3.4) | 5 (3.8) |
| PET-negative | 28 (16.1) | 18 (13.6) |
| . | Overall population . | Daratumumab-treated patients . |
|---|---|---|
| PM PET | ||
| No. of patients | 175 | 133 |
| Complete response | 113 (64.6) | 82 (61.7) |
| Unconfirmed complete response | 48 (27.4) | 40 (30.0) |
| PR | 14 (8.0) | 11 (8.3) |
| PET-negative | 161 (92.0) | 122 (91.7) |
| PET-positive | 14 (8.0) | 11 (8.3) |
| PM MFC | ||
| No. of patients | 174 | 132 |
| MFC-negative | 140 (80.5) | 109 (82.6) |
| PET-positive | 8 (4.6) | 6 (4.5) |
| PET-negative | 132 (76.0) | 103 (78.0) |
| MFC-positive | 34 (19.5) | 23 (17.4) |
| PET-positive | 6 (3.4) | 5 (3.8) |
| PET-negative | 28 (16.1) | 18 (13.6) |
Data are presented as number (%).